文献速递遗传性与小管间质肾病水电解质与酸碱急性肾损伤

Claudin-16自身抗体导致低镁血症、低钙血症及小管间质性肾病

Hypomagnesemia, Hypocalcemia, and Tubulointerstitial Nephropathy Caused by Claudin-16 Autoantibodies.
PubMed 文献 · J Am Soc Nephrol · 2022-06-21

一例成人获得性严重低镁血症、低钙血症、小管间质性肾病及快速进展性肾损伤患者,其表现与遗传性肾镁转运障碍相似,研究通过敲除小鼠、转染细胞及大鼠被动转移实验证实其低镁血症与针对claudin-16的自身抗体因果相关,免疫抑制治疗后GFR改善但低镁血症持续,随后诊断为高表达claudin-16 mRNA的肾癌。

要点

  • claudin-16自身抗体是获得性肾小管转运障碍及小管间质性肾病的新型自身免疫病因。
  • 对获得性不明原因低镁血症患者,或可筛查针对claudin-16及其他肾镁转运体或通道的自身抗体。
  • 免疫抑制治疗联合血浆置换与利妥昔单抗后患者GFR改善,但低镁血症持续。

核心结论

  • 致病性claudin-16自身抗体代表一种新型自身免疫病因,可导致特异性肾小管转运障碍和小管间质性肾病。
  • 对获得性不明原因低镁血症患者,或可筛查针对claudin-16及潜在其他肾镁转运体或通道的自身抗体。

研究设计与样本

  • 病例研究,结合claudin敲除小鼠实验、转染表达人claudin-16或claudin-19的小鼠肾细胞体外实验,以及给大鼠静脉注射患者或对照血清纯化IgG的被动转移实验。

主要发现

  • 敲除小鼠和体外转染细胞实验表明,患者低镁血症与针对claudin-16的自身抗体因果相关,claudin-16控制Henle环厚升支旁细胞镁重吸收。
  • 给大鼠静脉注射患者血清纯化IgG可诱导明显的尿镁流失。
  • 免疫抑制治疗联合血浆置换与利妥昔单抗与患者GFR改善相关,但低镁血症持续。
  • 患者随后被诊断为肾癌,该肿瘤高表达claudin-16 mRNA。

临床怎么用

  • 对获得性不明原因低镁血症患者,或可筛查针对claudin-16及潜在其他肾镁转运体或通道的自身抗体。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic hypomagnesemia is commonly due to diarrhea, alcoholism, and drugs. More rarely, it is caused by genetic defects in the effectors of renal magnesium reabsorption. METHODS: In an adult patient with acquired severe hypomagnesemia, hypocalcemia, tubulointerstitial nephropathy, and rapidly progressing kidney injury, similarities between the patient's presentation and features of genetic disorders of renal magnesium transport prompted us to investigate whether the patient had an acquired autoimmune cause of renal magnesium wasting. To determine if the patient's condition might be explained by autoantibodies directed against claudin-16 or claudin-19, transmembrane paracellular proteins involved in renal magnesium absorption, we conducted experiments with claudin knockout mice and transfected mouse kidney cells expressing human claudin-16 or claudin-19. We also examined effects on renal magnesium handling in rats given intravenous injections of IgG purified from sera from the patient or controls. RESULTS: Experiments with the knockout mice and in vitro transfected cells demonstrated that hypomagnesemia in the patient was causally linked to autoantibodies directed against claudin-16, which controls paracellular magnesium reabsorption in the thick ascending limb of Henle's loop. Intravenous injection of IgG purified from the patient's serum induced a marked urinary waste of magnesium in rats. Immunosuppressive treatment combining plasma exchange and rituximab was associated with improvement in the patient's GFR, but hypomagnesemia persisted. The patient was subsequently diagnosed with a renal carcinoma that expressed a high level of claudin-16 mRNA. CONCLUSIONS: Pathogenic claudin-16 autoantibodies represent a novel autoimmune cause of specific renal tubular transport disturbances and tubulointerstitial nephropathy. Screening for autoantibodies targeting claudin-16, and potentially other magnesium transporters or channels in the kidney, may be warranted in patients with acquired unexplained hypomagnesemia.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Figueres L, Bruneau S, Prot-Bertoye C, et al. Hypomagnesemia, Hypocalcemia, and Tubulointerstitial Nephropathy Caused by Claudin-16 Autoantibodies. J Am Soc Nephrol. 2022. PMID: 35728884. doi:10.1681/ASN.2022010060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。